Literature DB >> 28935032

Effect of Definition on Incidence and Prognosis of Type 2 Myocardial Infarction.

Thomas Nestelberger1, Jasper Boeddinghaus1, Patrick Badertscher2, Raphael Twerenbold3, Karin Wildi2, Dominik Breitenbücher2, Zaid Sabti2, Christian Puelacher2, Maria Rubini Giménez2, Nikola Kozhuharov2, Ivo Strebel2, Lorraine Sazgary2, Deborah Schneider4, Janina Jann4, Jeanne du Fay de Lavallaz2, Òscar Miró5, F Javier Martin-Sanchez6, Beata Morawiec7, Damian Kawecki7, Piotr Muzyk7, Dagmar I Keller8, Nicolas Geigy9, Stefan Osswald4, Tobias Reichlin2, Christian Mueller10.   

Abstract

BACKGROUND: Uncertainties regarding the most appropriate definition and treatment of type 2 myocardial infarction (T2MI) due to supply-demand mismatch have contributed to inconsistent adoption in clinical practice.
OBJECTIVES: This study sought a better understanding of the effect of the definition of T2MI on its incidence, treatment, and event-related mortality, thereby addressing an important unmet clinical need.
METHODS: The final diagnosis was adjudicated in patients presenting with symptoms suggestive of myocardial infarction by 2 independent cardiologists by 2 methods: 1 method required the presence of coronary artery disease, a common interpretation of the 2007 universal definition (T2MI2007); and 1 method did not require coronary artery disease, the 2012 universal definition (T2MI2012).
RESULTS: Overall, 4,015 consecutive patients were adjudicated. The incidence of T2MI based on the T2MI2007 definition was 2.8% (n = 112). The application of the more liberal T2MI2012 definition resulted in an increase of T2MI incidence of 6% (n = 240), a relative increase of 114% (128 reclassified patients, defined as T2MI2012reclassified). Among T2MI2007, 6.3% of patients received coronary revascularization, 22% dual-antiplatelet therapy, and 71% high-dose statin therapy versus 0.8%, 1.6%, and 31% among T2MI2012reclassified patients, respectively (all p < 0.01). Cardiovascular mortality at 90 days was 0% among T2MI2012reclassified, which was similar to patients with noncardiac causes of chest discomfort (0.2%), and lower than T2MI2007 (3.6%) and type 1 myocardial infarction (T1MI) (4.8%) (T2MI2012reclassified vs. T2MI2007 and T1MI: p = 0.03 and 0.01, respectively).
CONCLUSIONS: T2MI2012reclassified has a substantially lower event-related mortality rate compared with T2MI2007 and T1MI. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study; NCT00470587).
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  diagnosis; high-sensitivity cardiac troponin; type 2 myocardial infarction

Mesh:

Year:  2017        PMID: 28935032     DOI: 10.1016/j.jacc.2017.07.774

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  26 in total

1.  Variations on classification of main types of myocardial infarction: a systematic review and outcome meta-analysis.

Authors:  Kris G Vargas; Paul M Haller; Bernhard Jäger; Maximilian Tscharre; Ronald K Binder; Christian Mueller; Bertil Lindahl; Kurt Huber
Journal:  Clin Res Cardiol       Date:  2018-12-07       Impact factor: 5.460

2.  Higher non-cardiac mortality and lesser impact of early revascularization in patients with type 2 compared to type 1 acute myocardial infarction: results from the Tokyo CCU Network registry.

Authors:  Satoshi Higuchi; Makoto Suzuki; Yu Horiuchi; Hiroyuki Tanaka; Mike Saji; Hideaki Yoshino; Ken Nagao; Takeshi Yamamoto; Morimasa Takayama
Journal:  Heart Vessels       Date:  2019-01-25       Impact factor: 2.037

Review 3.  Type 2 Myocardial Infarction: Evolving Approaches to Diagnosis and Risk-Stratification.

Authors:  Andrew R Chapman; Yader Sandoval
Journal:  Clin Chem       Date:  2021-01-08       Impact factor: 8.327

4.  Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.

Authors:  Christoph B Olivier; Hillary Mulder; William R Hiatt; W Schuyler Jones; F Gerry R Fowkes; Frank W Rockhold; Jeffrey S Berger; Iris Baumgartner; Peter Held; Brian G Katona; Lars Norgren; Juuso Blomster; Manesh R Patel; Kenneth W Mahaffey
Journal:  JAMA Cardiol       Date:  2019-01-01       Impact factor: 14.676

5.  Blood and imaging biomarkers in type 2 myocardial infarction.

Authors:  Andrew R Chapman; Bertil Lindahl; Nicholas L Mills; Christian Mueller
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2022-03-16

6.  A Novel Electrocardiographic Score Predicts the Severity of Coronary Artery Disease and Clinical Outcomes in Patients with Non-ST Segment Elevation Myocardial Infarction.

Authors:  Aziz Inan Celik; Tahir Bezgin; Metin Cagdas; Tufan Cınar; Ayca Gumusdag
Journal:  Acta Cardiol Sin       Date:  2022-05       Impact factor: 1.800

7.  Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort.

Authors:  Claire E Raphael; Véronique L Roger; Yader Sandoval; Mandeep Singh; Malcolm Bell; Amir Lerman; Charanjit S Rihal; Bernard J Gersh; Bradley Lewis; Ryan J Lennon; Allan S Jaffe; Rajiv Gulati
Journal:  Circulation       Date:  2020-01-06       Impact factor: 29.690

8.  Characteristics and Outcomes of Type 1 versus Type 2 Perioperative Myocardial Infarction After Noncardiac Surgery.

Authors:  Nathaniel R Smilowitz; Binita Shah; Kurt Ruetzler; Santiago Garcia; Jeffrey S Berger
Journal:  Am J Med       Date:  2021-09-22       Impact factor: 4.965

9.  High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction.

Authors:  Andrew R Chapman; Philip D Adamson; Anoop S V Shah; Atul Anand; Fiona E Strachan; Amy V Ferry; Kuan Ken Lee; Colin Berry; Iain Findlay; Anne Cruikshank; Alan Reid; Alasdair Gray; Paul O Collinson; Fred Apple; David A McAllister; Donogh Maguire; Keith A A Fox; Catalina A Vallejos; Catriona Keerie; Christopher J Weir; David E Newby; Nicholas L Mills
Journal:  Circulation       Date:  2019-10-07       Impact factor: 29.690

10.  Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction.

Authors:  John Hung; Andreas Roos; Erik Kadesjö; David A McAllister; Dorien M Kimenai; Anoop S V Shah; Atul Anand; Fiona E Strachan; Keith A A Fox; Nicholas L Mills; Andrew R Chapman; Martin J Holzmann
Journal:  Eur Heart J       Date:  2021-07-08       Impact factor: 35.855

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.